# ACTU (Actuate Therapeutics, Inc.) - SEC EDGAR Financial Statements

> Actuate Therapeutics, Inc. reported $3.22M in total assets and a net loss of $18.47M through December 31, 2025 from SEC EDGAR filings.

- Canonical: https://convexityos.com/fundamentals/ACTU
- Markdown: https://convexityos.com/fundamentals/ACTU.md
- SEC CIK: 0001652935
- Reporting currency: USD
- Latest filing period: September 30, 2026
- Last synced: Nov 21, 2026, 05:08 UTC
- Primary source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001652935&type=&dateb=&owner=include&count=40)

## Key Financial Metrics

| Metric | Period | Value | Notes |
| --- | --- | --- | --- |
| Revenue | FY 2025 | -- | Dec 31, 2025 |
| Operating Income | FY 2025 | -$18.74M | Operating profit |
| Net Income | FY 2025 | -$18.47M | GAAP bottom line |
| Diluted EPS | FY 2025 | -$0.76 | Split-adjusted |
| Free Cash Flow | FY 2025 | -- | Operating CF less CapEx |
| Cash & ST Investments | Sep 30, 2026 | $2.10M | Total debt: -- |

## Income Statement

### Income Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| Research & Development | $10.29M | $18.68M | $21.71M |
| Total Operating Expenses | $22.50M | $25.16M | $24.97M |
| **Operating Income** | -$22.50M | -$25.16M | -$24.97M |
| Interest Income | $288K | $222K | $353K |
| Interest Expense | $20K | $19K | $44K |
| Income Tax Expense | $800 | $800 | $0 |
| **Net Income** | -$22.23M | -$27.29M | -$24.74M |
| Basic EPS | -$1.06 | -$3.26 | -$17.24 |
| **Diluted EPS** | -$1.06 | -$3.26 | -$17.24 |
| Basic Shares Outstanding | 21.0M | 8.4M | 1.4M |
| Diluted Shares Outstanding | 21.0M | 8.4M | 1.4M |

### Income Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Research & Development | $1.81M | $2.07M | $2.57M | $2.13M | $2.18M | $2.76M | $3.22M | $3.69M |
| Total Operating Expenses | $3.44M | $4.91M | $5.71M | $4.69M | $5.47M | $5.97M | $6.37M | $6.56M |
| **Operating Income** | -$3.44M | -$4.91M | -$5.71M | -$4.69M | -$5.47M | -$5.97M | -$6.37M | -$6.56M |
| Interest Income | -- | $45K | $85K | $140K | $70K | $25K | $54K | $118K |
| Interest Expense | $5.1K | $5.1K | $5.1K | $5.1K | $5.1K | $5.1K | $5.1K | $5.1K |
| **Net Income** | -$3.42M | -$4.87M | -$5.63M | -$4.55M | -$5.41M | -$5.95M | -$6.32M | -$6.45M |
| Basic EPS | -$0.14 | -$0.20 | -$0.24 | -- | -$0.25 | -$0.30 | -$0.32 | -- |
| **Diluted EPS** | -$0.14 | -$0.20 | -$0.24 | -- | -$0.25 | -$0.30 | -$0.32 | -- |
| Basic Shares Outstanding | 24.2M | 23.9M | 23.5M | -- | 21.4M | 19.6M | 19.5M | -- |
| Diluted Shares Outstanding | 24.2M | 23.9M | 23.5M | -- | 21.4M | 19.6M | 19.5M | -- |

## Balance Sheet

### Balance Sheet (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| Cash & Cash Equivalents | $13.16M | $8.64M | -- |
| **Cash & Short-Term Investments** | $13.16M | $8.64M | -- |
| **Total Current Assets** | $13.64M | $9.21M | $3.00M |
| Other Non-Current Assets | $392K | $111K | $0 |
| **Total Non-Current Assets** | $392K | $111K | $0 |
| **Total Assets** | $14.04M | $9.32M | $3.00M |
| Accounts Payable | $1.52M | $1.92M | $3.42M |
| **Total Current Liabilities** | $5.71M | $8.80M | $6.92M |
| **Total Non-Current Liabilities** | $405K | $412K | $1.52M |
| **Total Liabilities** | $6.11M | $9.21M | $8.44M |
| Common Stock | $23 | $20 | $2 |
| Retained Earnings | -$154.6M | -$132.4M | -$105.1M |
| **Total Stockholders' Equity** | $7.92M | $104K | -$99.63M |
| Total Equity | $7.92M | $104K | -$99.63M |

### Balance Sheet (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash & Cash Equivalents | $2.10M | $4.43M | $8.13M | $13.16M | $16.92M | $6.49M | $3.89M | $8.64M |
| **Cash & Short-Term Investments** | $2.10M | $4.43M | $8.13M | $13.16M | $16.92M | $6.49M | $3.89M | $8.64M |
| **Total Current Assets** | $2.65M | $4.75M | $8.52M | $13.64M | $17.44M | $6.69M | $4.25M | $9.21M |
| Other Non-Current Assets | $571K | $451K | $392K | $392K | $270K | $280K | $234K | $111K |
| **Total Non-Current Assets** | $571K | $451K | $392K | $392K | $270K | $280K | $234K | $111K |
| **Total Assets** | $3.22M | $5.20M | $8.91M | $14.04M | $17.71M | $6.97M | $4.48M | $9.32M |
| Accounts Payable | $891K | $1.08M | $1.20M | $1.52M | $1.25M | $3.17M | $2.64M | $1.92M |
| **Total Current Liabilities** | $3.62M | $3.81M | $4.72M | $5.71M | $6.37M | $9.20M | $9.15M | $8.80M |
| **Total Non-Current Liabilities** | $405K | $405K | $405K | $405K | $405K | $422K | $417K | $412K |
| **Total Liabilities** | $4.03M | $4.21M | $5.13M | $6.11M | $6.78M | $9.62M | $9.57M | $9.21M |
| Common Stock | $25 | $24 | $24 | $23 | $23 | $20 | $20 | $20 |
| Retained Earnings | -$168.5M | -$165.1M | -$160.2M | -$154.6M | -$150.1M | -$144.6M | -$138.7M | -$132.4M |
| **Total Stockholders' Equity** | -$809K | $989K | $3.78M | $7.92M | $10.94M | -$2.65M | -$5.09M | $104K |
| Total Equity | -$809K | $989K | $3.78M | $7.92M | $10.94M | -$2.65M | -$5.09M | $104K |

## Cash Flow Statement

### Cash Flow Statement (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| Net Income | -$22.23M | -$27.29M | -$24.74M |
| Stock-Based Compensation | $6.05M | $2.00M | $424K |
| Change in Payables | -$513K | -$1.50M | $1.29M |
| **Operating Cash Flow** | -$19.21M | -$21.84M | -$21.63M |
| Common Stock Issued | $3.83M | $0 | -- |
| **Financing Cash Flow** | $23.72M | $27.53M | $4.13M |
| **Net Change in Cash** | $4.52M | $5.68M | -$17.49M |

### Cash Flow Statement (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Net Income | -$3.42M | -$4.87M | -$5.63M | -$4.55M | -$5.41M | -$5.95M | -$6.32M | -$6.45M |
| Stock-Based Compensation | $971K | $1.34M | $1.36M | $1.54M | $1.80M | $1.58M | $1.13M | $1.19M |
| Change in Payables | -$280K | -$151K | -$323K | $186K | -$1.83M | $508K | $622K | -$303K |
| **Operating Cash Flow** | -$2.95M | -$4.41M | -$5.02M | -$3.74M | -$6.68M | -$4.17M | -$4.62M | -$4.77M |
| Common Stock Issued | $774K | $732K | $520K | $3.83M | $0 | $0 | $0 | -- |
| **Financing Cash Flow** | $627K | $697K | -$8.1K | -$29K | $17.11M | $6.78M | -$133K | -$109K |
| **Net Change in Cash** | -$2.32M | -$3.71M | -$5.03M | -$3.77M | $10.43M | $2.60M | -$4.75M | -$4.88M |

## Profitability Ratios & YoY Growth

### Profitability Ratios & YoY Growth (Annual)

| Line Item | FY 2025 | FY 2024 | FY 2023 |
| --- | --- | --- | --- |
| Return on Equity (ROE) | -280.5% | -26189.1% | -- |
| Return on Assets (ROA) | -158.4% | -292.8% | -826.0% |
| Current Ratio | 2.39x | 1.05x | 0.43x |
| Quick Ratio | 2.31x | 0.98x | -- |

### Profitability Ratios & YoY Growth (Quarterly)

| Line Item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Return on Equity (ROE) | -- | -2067.8% | -569.1% | -280.5% | -220.6% | -- | -- | -26189.1% |
| Return on Assets (ROA) | -573.7% | -393.4% | -241.7% | -158.4% | -136.2% | -354.2% | -564.5% | -292.8% |
| Current Ratio | 0.73x | 1.25x | 1.80x | 2.39x | 2.74x | 0.73x | 0.46x | 1.05x |
| Quick Ratio | 0.58x | 1.16x | 1.72x | 2.31x | 2.66x | 0.71x | 0.42x | 0.98x |

## Related Companies

[AMZN (Amazon.com, Inc.)](https://convexityos.com/fundamentals/AMZN), [WMT (Walmart Inc.)](https://convexityos.com/fundamentals/WMT), [AAPL (Apple Inc.)](https://convexityos.com/fundamentals/AAPL), [GOOG (Alphabet Inc.)](https://convexityos.com/fundamentals/GOOG), [UNH (UnitedHealth Group Incorporated)](https://convexityos.com/fundamentals/UNH), [CVS (CVS HEALTH Corp)](https://convexityos.com/fundamentals/CVS), [MCK (McKESSON CORPORATION)](https://convexityos.com/fundamentals/MCK), [BRK-A (Berkshire Hathaway Inc.)](https://convexityos.com/fundamentals/BRK-A)

---

## About Convexity

Published by [Convexity](https://convexityos.com/), a primary-source financial intelligence terminal built on SEC EDGAR filings, XBRL financial statements, options, macro data, and cited AI research. Free tier with no card and published prices at https://convexityos.com/pricing; Streamable HTTP MCP server at https://convexityos.com/mcp; full site index at https://convexityos.com/llms.txt.
